Therapy of Early Chronic Phase CML With Gleevec

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

November 30, 2002

Study Completion Date

August 31, 2013

Conditions
Leukemia, Myeloid, Chronic-Phase
Interventions
DRUG

Gleevec

Starting dose of 400 mg orally daily.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER